Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05962242 · ClinicalTrials.gov registry record · Phase 2
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
A Phase 2 study of Squamous Cell Carcinoma of the Oropharynx, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 5
- Study locations
NCT05962242 is a Phase 2 study of Squamous Cell Carcinoma of the Oropharynx that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 90 participants, above the 64-participant average among 6 other Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (41% higher). The trial reports 5 study locations across 2 states.
The verdict
NCT05962242, a Phase 2 study of Squamous Cell Carcinoma of the Oropharynx, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 5
- Study locations
Study Summary
The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (5)
Virginia
- University of Virginia - Charlottesville
- Eastern Virginia Medical School - Norfolk
- Bon Secours - Richmond
- Virginia Commonwealth University - Richmond
Florida
- Miami Cancer Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-06-28 |
| Est. Completion | 2029-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05962242
The ClinicalTrials.gov registry entry for NCT05962242 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 64-participant average among 6 other Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (41% higher). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma of the Oropharynx appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT05962242 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Virginia, Florida.
Frequently Asked Questions
What is clinical trial NCT05962242 about?
NCT05962242 is a clinical study titled "HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma". The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.
What is the current status of trial NCT05962242?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-06-28. Estimated completion is 2029-11-01.
What conditions does trial NCT05962242 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Oropharynx.
What interventions are being tested in trial NCT05962242?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05962242?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05962242 being conducted?
This trial has 5 study locations across Florida, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of the Oropharynx
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
RECRUITING · Phase 2
-
Safety and Efficacy of APG-157 in Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · NA
-
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
COMPLETED · Phase 1
-
Saliva-based Detection of CD44
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.